Effects of Cromolyn on Codeine‐Induced Histamine Release <i>in Vivo</i>

Ting, Stanislaus; Reimann, E.; Zweiman, Burton

doi:10.1111/j.1398-9995.1984.tb00869.x

Cited by 8 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike Haider (7), Zachariae et al {!5) were also unable to show SCG superior to placebo. Our results are consistent with the demonstration that SCG does not modulate human allergic skin reactions when injected intradermally together with ragweed allergen in ragweed allergic subjects (13) or together with codeine (14). SCG appears to stabilize connective tissue mast cells but not mucosal mast cells (4).…”

Section: Discussionsupporting

confidence: 91%

Topical Sodium Cromoglycate in Atopic Dermatitis A Disappointing but Informative Trial

Kjellman

Gustafsson

1986

Allergy

View full text Add to dashboard Cite

Forty children with atopic eczema requiring topical steroids entered a double-blind group comparative study over 12 weeks and were randomized to either 4% sodium cromoglycate (SCG) in an oil-in-water cream or matching placebo cream. The eczema was evaluated on area charts for 20 parts of the body at five clinic visits. In addition, the families kept diaries on symptoms and treatment. After 3 weeks there were small but statistically significant decreases in severity scores recorded at the clinical visits in the SCG group compared with small increases in the placebo group. However, there were no statistically significant differences in the diary card data during the first 3 weeks of treatment or in any other period, nor were significant differences found in any efficacy data collected during the other 9 weeks of the trial. There were no marked differences in treatment opinions, unusual symptoms, skin infections, use of topical steroids or drugs, or acceptability data between the groups. Staphylococcus aureus was found once or twice in cultures from eczema lesions in 31 of 40 children with no marked group difference. The trial showed that there is great need for improved information, family support and topical as well as general treatment in childhood atopic eczema, but topical SCG did not relieve the patients' eczema.

show abstract

Section: Discussionsupporting

confidence: 91%

Topical Sodium Cromoglycate in Atopic Dermatitis A Disappointing but Informative Trial

Kjellman

Gustafsson

1986

Allergy

View full text Add to dashboard Cite

show abstract

“…It is therefore of interest to study the effect on antigen wealing of the chromones which are known to inhibit release of inflammatory mediators from the mast cell. This has not been possible in human skin in vivo after oral administration because of poor absorption of these drugs and there has been only limited study of the effect of intradermally injected sodium cromoglycate (Ting et al, 1984). We therefore took advantage of the fact that nedocromil (9-ethyl-6,9 dihydro-4,6 dioxo 10 propyl-4 H pyrano (3,2-g) quinoline-2-8 dicarboxylic acid, FPL 59002) in its disodium salt is soluble in water forming an ionic solution suitable for delivery into the skin by iontophoresis, to study the influence of chromones on skin wealing reactions to histamine, 48/80 and house dust mite antigen.…”

Section: Introductionmentioning

confidence: 99%

The effect of nedocromil on weal reactions in human skin.

Humphreys

Shuster

1987

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Nedocromil 2% iontophoresed into human skin had no effect on wealing produced by intradermal histamine, 48/80 or house dust mite antigen. 2 Iontophoresis of 0.002-2% nedocromil itself resulted in dose-related wealing.3 This wealing was reduced by 62 ± 8% s.e. mean by the Hl-receptor antagonist terfenadine which decreased histamine wealing by 68 ± 2% s.e. mean. 4 Nedocromil may therefore act as a weak agonist on a skin mast cell receptor concerned with histamine release.

show abstract